text:
Month: June 2019
Blog Stats
- 165,494 hits
About Letstakereview
Letstakereview is a blog which was launched in 2015 and offers news on extreme variety of items including smartphones ,fitness bands ,headphones and so on.
Blogger shares their experience to the world which makes it easier for the visitors to experience stuff without buying it and comes up with an easy conclusion whether to buy it or not.
Feel free to contact us if you have any query or facing any problem at
Email: email@example.com
About Author
I Dishu khanna, Founder And CEO of this Firm Letstakereview from New Delhi. Blogging is my passion as I can share my views about new gadgets to other buyers and other gadget geeks like me.
I Consider Blogging as a way to explore new things, new gadgets and new innovations.


text:
Subscribe To Dawn Of The Planet Of The Apes Sequel, The Poltergeist Remake And More Get New Release Dates Updates
I've already subscribed
Dawn of the Planet of the Apes won't be out until this summer, but 20th Century Fox is already getting very serious about the second sequel in the rebooted Planet of the Apes franchise. One week ago it was reported that Dawn director Matt Reeves had signed a deal to direct the movie, and now the studio has given the project an official release date. Fox is now planning to get the next film in the series into theaters on July 29, 2016, a little two years after part two comes out. But that's not the only scheduling move that we've learned about today.
According to Box Office Mojo, Fox has taken today to announce some big shifts in their 2014, 2015 and 2016 lineups. In addition to the untitled third Planet of the Apes movie, the studio has also scheduled new dates for the Poltergeist remake, The Longest Ride, Night At The Museum 3, and Let's Be Cops.
After spending many, many years in development hell, the Poltergeist remake has finally come together, and is now set to come out in theaters as a bit of counter-programming on Valentine's Day weekend 2015. The film certainly has some interesting things working in its favor, including Monster House's Gil Kenan in the director's chair and a cast that includes Sam Rockwell, Jared Harris, and Rosemarie DeWitt, but it will face serious competition in the highly anticipated Fifty Shades of Grey adaptation that is coming out the same weekend.
The Longest Ride, which is the next big Nicholas Sparks adaptation, was also originally supposed to come out on February 13, 2015, but now Fox has pushed it along to April 3rd. The film doesn't currently have a director or any stars attached, but what it does have is a few new titles that it will be opening against. Focus Features' Insidious Chapter 3 will be doing its best to lure audiences away with a few spring scares, while Keanu Reeves and Rachel McAdams will have a different kind of boy-girl relationship in the sci-fi story Passengers.
Of the release date moves, the one for Shawn Levy's Night At The Museum 3 is by far the smallest. Originally Fox was planning to have the film in theaters on Christmas Day of this year, but now they will be aiming to have it ready one week earlier on December 19th. This will technically mean that it will be sharing an opening weekend with Peter Jackson's The Hobbit: There And Back Again (which will be out on December 17th) and the Annie remake, but the shift does move the film away from the Disney musical Into The Woods and Angelina Jolie's war drama Unbroken. In addition to franchise star Ben Stiller, the new sequel will also feature Ricky Gervais, Rebel Wilson, Steve Coogan, Owen Wilson, Robin Williams and Dan Stevens.
Finally there's the comedy Let's Be Cops. Directed by Luke Greenfield, the film will feature Damon Wayans Jr and Jake Johnson as a pair of ordinary guys who decide to pretend to be police officers. As interesting as that may sound, however, it would appear that Fox doesn't have too much confidence in it, setting the movie to come out in the waning days of summer on August 13th of this year. It's definitely possible that this could wind up being a late-summer surprise, but the release date makes me nervous.

subset: commoncrawl


text: Guangzhou Yuegao Import & Export Co. Ltd was established in 2008. We are devoted to becoming a professional vendor of cleaning products and hotel products. Our business scope covers industrial machines, trash bins, hotel carts, mop wringer buckets, caution boards, soap dispensers, paper dispensers, mops, tools, hotel linens and other related items.We continue to expand our product line to fulfill all kinds of customers' requirements. Our products are exported to North America, Europe, the Middle East and Asia.Contact us today to begin sourcing. [Details]


text: Featuring saxophonist, Levi Saelua, and the Shine House Jazz Band! Come in and be part of the music. Bring your instrument and get on stage, or just enjoy the jam with any wine, beer, coffee, or tea from our extensive selections. Sacramento's coolest Open Jazz Jams happen every Thursday Night at Shine starting at 8pm. Be cool. Be here.


text:
NDC 61919-613 Trazodone Hydrochloride
Trazodone Hydrochloride
NDC Product Code 61919-613
NDC Code: 61919-613
Proprietary Name: Trazodone Hydrochloride What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name: Trazodone Hydrochloride What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
NDC Code Structure
- 61919 - Direct_rx
- 61919-613 - Trazodone Hydrochloride
NDC Product Information
Trazodone Hydrochloride with NDC 61919-613 is a a human prescription drug product labeled by Direct_rx. The generic name of Trazodone Hydrochloride is trazodone hydrochloride. The product's dosage form is tablet and is administered via oral form.
Dosage Form: Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the "Document Type" field of the Structured Product Listing.
Trazodone Hydrochloride Active Ingredient(s)What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Administration Route(s)What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.
- Oral - Administration to or by way of the mouth.
Pharmacological Class(es)What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.
- Serotonin Reuptake Inhibitor - [EPC] (Established Pharmacologic Class)
Product Labeler InformationWhat is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.
Labeler Name: Direct_rx
Labeler Code: 61919
FDA Application Number: ANDA205253 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. "part 341"). For unapproved drugs, this field will be null.
Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Start Marketing Date: 08-19-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.
Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA's requests for correction to deficient or non-compliant submissions. Values = 'Y' or 'N'.
* Please review the disclaimer below.
Information for Patients
Trazodone is pronounced as (traz' oh done)
Why is trazodone medication prescribed?
Trazodone is used to treat depression. Trazodone is in a class of medications called serotonin modulators. It works by increasing the amount of serotonin, a natural subst...
[Read More]
* Please review the disclaimer below.
Trazodone Hydrochloride Product Labeling Information
The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.
Product Labeling Index
- Boxed Warning Section
- Indications & Usage Section
- Dosage & Administration Section
- Dosage Forms & Strengths Section
- Contraindications Section
- Warnings And Precautions Section
- Adverse Reactions Section
- Drug Interactions Section
- Use In Specific Populations Section
- Drug Abuse And Dependence Section
- Overdosage Section
- Description Section
- Clinical Pharmacology Section
- Nonclinical Toxicology Section
- Clinical Studies Section
- How Supplied Section
- Patient Medication Information Section
Boxed Warning Section
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGSAntidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of trazodone hydrochloride tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Trazodone hydrochloride tablets are not approved for use in pediatric patients [see Warnings and Precautions (5.1) and Patient Counseling Information (17.1)].
Indications & Usage Section
Trazodone hydrochloride tablets USP are indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of trazodone hydrochloride tablets USP has been established in trials with the immediate release formulation of trazodone [see Clinical Studies (14)].
Dosage & Administration Section
- The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. Trazodone hydrochloride tablets should be taken shortly after a meal or light snack.Dose SelectionAn initial dose of 150 mg/day in divided doses is suggested. The dose may be increased by 50 mg/day every 3 to 4 days. The maximum dose for outpatients usually should not exceed 400 mg/day in divided doses. Inpatients (i.e., more severely depressed patients) may be given up to but not in excess of 600 mg/day in divided dosesOnce an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.Patients should be monitored for withdrawal symptoms when discontinuing treatment with trazodone hydrochloride tablets. The dose should be gradually reduced whenever possible [see Warnings andPrecautions (
- 5.12)].
- Maintenance TreatmentThe efficacy of trazodone hydrochloride tablets for the maintenance treatment of MDD has not been evaluated. While there is no body of evidence available to answer the question of how long a patient treated with trazodone hydrochloride tablets should continue the drug, it is generally recommended that treatment be continued for several months after an initial response. Patients should be maintained on the lowest effective dose and be periodically reassessed to determine the continued need for maintenance treatment.Important Administration InstructionsTrazodone hydrochloride tablets are scored to provide flexibility in dosing.Trazodone hydrochloride tablets can be swallowed whole or administered as a half tablet by breaking the tablet along the score line.
Dosage Forms & Strengths Section
Trazodone hydrochloride tablets are available in the following strengths:50 mg- White, round, compressed tablet, debossed "PLIVA 433" on one side and scored on the other side.100 mg- White, round, compressed tablets, debossed "PLIVA 434" on one side and scored on the other side.150 mg- White, trapezoid, flat-face, beveled edge tablet, scored and debossed as "PLIVA" and "441" on one side and tri-scored and debossed as "50" in each section on the other side.
Contraindications Section
Warnings And Precautions Section
5.1 Clinical Worsening and Suicide RiskPatients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders and these disorders themselves are the strongest predictors of suicide. There has been a long standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1.Table 1Age RangeDrug-Placebo Difference in Number of Cases of Suicidality per 1,000 Patients TreatedIncreases Compared to Placebo< 1814 additional cases18 to 245 additional casesDecreases Compared to Placebo25 to 641 fewer case≥ 656 fewer cases No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for trazodone should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.5.2 Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-Like ReactionsThe development of a potentially life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions have been reported with antidepressants alone and may occur with trazodone treatment, but particularly with concomitant use of other serotoninergic drugs (including SSRIs, SNRIs and triptans) and with drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs]), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, and hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, and diarrhea). Serotonin syndrome, in its most severe form, can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes.Treatment with trazodone hydrochloride tablets and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above reactions occur and supportive symptomatic treatment should be initiated.Trazodone hydrochloride tablets should not be used within 14 days of an MAOI [see Warnings andPrecautions (
5.8) and Drug Interactions (
If concomitant treatment with trazodone hydrochloride tablets and an SSRI, SNRI or a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.The concomitant use of trazodone hydrochloride tablets with serotonin precursors (such as tryptophan) is not recommended.5.3 Screening Patients for Bipolar Disorder and Monitoring for Mania/HypomaniaA major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described for clinical worsening and suicide risk represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that trazodone hydrochloride tablets are not approved for use in treating bipolar depression.5.4 QT Prolongation and Risk of Sudden DeathTrazodone is known to prolong the QT/QTc interval. Some drugs that prolong the QT/QTc interval can cause torsade de pointes with sudden, unexplained death. The relationship of QT prolongation is clearest for larger increases (20 msec and greater), but it is possible that smaller QT/QTc prolongations may also increase risk, especially in susceptible individuals, such as those with hypokalemia, hypomagnesemia, or a genetic predisposition to prolonged QT/QTc.Although torsade de pointes has not been observed with the use of trazodone hydrochloride tablets at recommended doses in premarketing trials, experience is too limited to rule out an increased risk. However, there have been postmarketing reports of torsade de pointes with the immediate-release form of trazodone (in the presence of multiple confounding factors), even at doses of 100 mg per day or less.5.5 Use in Patients With Heart DiseaseTrazodone hydrochloride is not recommended for use during the initial recovery phase of myocardial infarction.Caution should be used when administering trazodone hydrochloride tablets to patients with cardiac disease and such patients should be closely monitored, since antidepressant drugs (including trazodone hydrochloride) may cause cardiac arrhythmias.QT prolongation has been reported with trazodone therapy [see Warnings and Precautions (5.4)]. Clinical studies in patients with preexisting cardiac disease indicate that trazodone hydrochloride may be arrhythmogenic in some patients in that population. Arrhythmias identified include isolated PVCs, ventricular couplets, tachycardia with syncope, and torsade de pointes. Postmarketing events have been reported at doses of 100 mg or less with the immediate-release form of trazodone.Concomitant administration of drugs that prolong the QT interval or that are inhibitors of CYP3A4 may increase the risk of cardiac arrhythmia.5.6 Orthostatic Hypotension and SyncopeHypotension, including orthostatic hypotension and syncope has been reported in patients receiving trazodone hydrochloride. Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug.5.7 Abnormal BleedingPostmarketing data have shown an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal (GI) bleeding. While no association between trazodone and bleeding events, in particular GI bleeding, was shown, patients should be cautioned about potential risk of bleeding associated with the concomitant use of trazodone and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding. Other bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.5.8 Interaction With MAOIsIn patients receiving serotonergic drugs in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, autonomic instability with rapid fluctuation in vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued antidepressant treatment and have been started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Furthermore, limited animal data on the effects of combined use of serotonergic antidepressants and MAOIs suggest that these drugs may act synergistically to elevate blood pressure and evoke behavioral excitation. Therefore, it is recommended that trazodone hydrochloride tablets should not be used in combination with an MAOI or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 14 days should be allowed after stopping trazodone hydrochloride tablets before starting an MAOI.5.9 PriapismRare cases of priapism (painful erections greater than 6 hours in duration) were reported in men receiving trazodone. Priapism, if not treated promptly, can result in irreversible damage to the erectile tissue. Men who have an erection lasting greater than 6 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention [see Adverse Reactions (
6.2) and Overdosage (
Trazodone should be used with caution in men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie's disease).5.10 HyponatremiaHyponatremia may occur as a result of treatment with antidepressants. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with antidepressants. Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. Discontinuation of trazodone hydrochloride tablets should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.5.11 Potential for Cognitive and Motor ImpairmentTrazodone hydrochloride tablets may cause somnolence or sedation and may impair the mental and/or physical ability required for the performance of potentially hazardous tasks. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the drug treatment does not affect them adversely.5.12 Discontinuation SymptomsWithdrawal symptoms including anxiety, agitation and sleep disturbances, have been reported with trazodone. Clinical experience suggests that the dose should be gradually reduced before complete discontinuation of the treatment.
Adverse Reactions Section
The following serious adverse reactions are described elsewhere in the labeling:• Clinical Worsening and Suicide Risk [see Boxed Warning and Warnings and Precautions (
• Serotonin Syndrome or NMS-Like Reactions [see Warnings and Precautions (
• QT Prolongation and Risk of Sudden Death [see Warnings and Precautions (
• Orthostatic Hypotension [see Warnings and Precautions (
• Abnormal Bleeding Events [see Warnings and Precautions (
• Priapism [see Warnings and Precautions (
• Hyponatremia [see Warnings and Precautions (
• Cognitive and Motor Impairment [see Warnings and Precautions (
• Discontinuation Symptoms [see Warnings and Precautions (
The most common adverse reactions (reported in ≥ 5% and at twice the rate of placebo) are:Somnolence/sedation, dizziness, constipation, vision blurred.Table 2 presents the summary of adverse events (AEs) leading to discontinuation of trazodone hydrochloride tablets treatment with an incidence of at least 1% and at least twice that for placebo.Table 2: Adverse Reactions With Discontinuation as
Action Taken (≥ 1%) Incidence and Incidence 2x PlaceboTrazodoneN = 202
Somnolence/Sedation8 (4%)Dizziness7 (3.5%)Confusional state2 (1%)Coordination abnormal2 (1%)Headache2 (1%)Nausea2 (1%)Balance disorder/Gait disturbance2 (1%)6.1 Clinical Studies ExperienceThe table below is presented solely to indicate the relative frequency of adverse events reported in representative controlled clinical studies conducted to evaluate the safety and efficacy of trazodone hydrochloride.The figures cited cannot be used to predict concisely the incidence of untoward events in the course of usual medical practice where patient characteristics and other factors often differ from those which prevailed in the clinical trials. These incidence figures, also, cannot be compared with those obtained from other clinical studies involving related drug products and placebo as each group of drug trials is conducted under a different set of conditions.*Incidence less than 1%
Table 3: Adverse Reactions: Percentage of Patients (> 2%) as Observed in Controlled Clinical StudiesInpatientsOutpatientsTrazodonePlaceboTrazodonePlaceboNumber of Patients14295157158% of Patients ReportingAllergicSkin Condition/Edema184.108.40.206AutonomicBlurred Vision18.104.22.168.8Constipation184.108.40.206Dry Mouth14.88.433.820.3CardiovascularHypertension18.104.22.168*Hypotension71.13.80Shortness of Breath*1.11.30Syncope184.108.40.206.3Tachycardia/Palpitations0077CNSAnger/Hostility188.8.131.52.5Confusion4.905.77.6Decreased Concentration184.108.40.206Disorientation2.10*0Dizziness/Light-Headedness19.75.32815.2Drowsiness23.96.340.819.6Excitement184.108.40.206.7Fatigue184.108.40.206.5Headache9.95.319.815.8Insomnia9.910.56.412Impaired Memory1.40**Nervousness14.810.56.48.2GastrointestinalAbdominal/Gastric Disorder18.104.22.168.4Bad Taste in Mouth1.4000Diarrhea01.14.51.9Nausea/Vomiting184.108.40.206.5MusculoskeletalMusculoskeletal Aches/Pains220.127.116.11.5NeurologicalIncoordination4.901.90Paresthesia1.400*Temors18.104.22.168.8Sexual FunctionDecreased Libido*1.11.3*OtherDecreased Appetite3.55.30*Eyes Red/Tired/Itching2.8000Head Full-Heavy2.8000Malaise2.8000Nasal/Sinus Congestion2.805.73.2Nightmares/Vivid Dreams*184.108.40.206Sweating/Clamminess1.41.1**Tinnitus1.400*Weight Gain1.404.51.9Weight Loss*22.214.171.124Occasional sinus bradycardia has occurred in long-term studies.In addition to the relatively common (i.e., greater than 1%) untoward events enumerated above, the following adverse events have been reported to occur in association with the use of trazodone hydrochloride in the controlled clinical studies: akathisia, allergic reaction, anemia, chest pain, delayed urine flow, early menses, flatulence, hallucinations/delusions, hematuria, hyper-salivation, hypomania, impaired speech, impotence, increased appetite, increased libido, increased urinary frequency, missed periods, muscle twitches, numbness, and retrograde ejaculation.6.2 Postmarketing ExperienceSpontaneous reports regarding trazodone hydrochloride received from postmarketing experience include the following: abnormal dreams, agitation, alopecia, anxiety, aphasia, apnea, ataxia, breast enlargement or engorgement, cardiospasm, cerebrovascular accident, chills, cholestasis, clitorism, congestive heart failure, diplopia, edema, extrapyramidal symptoms, grand mal seizures, hallucinations, hemolytic anemia, hirsutism, hyperbilirubinemia, increased amylase, increased salivation, insomnia, leukocytosis, leukonychia, jaundice, lactation, liver enzyme alterations, methemoglobinemia, nausea/vomiting (most frequently), paresthesia, paranoid reaction, priapism [see Warnings and Precautions (
5.9) and Patient Counseling Information (
17.1)], pruritus, psoriasis, psychosis, rash, stupor, inappropriate ADH syndrome, tardive dyskinesia, unexplained death, urinary incontinence, urinary retention, urticaria, vasodilation, vertigo, and weakness.
Cardiovascular system effects which have been reported include the following: conduction block, orthostatic hypotension and syncope, palpitations, bradycardia, atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia, ventricular ectopic activity, including ventricular tachycardia and QT prolongation. In postmarketing surveillance, prolonged QT interval, torsade de pointes, and ventricular tachycardia have been reported with the immediate-release form of trazodone at doses of 100 mg per day or less [see Warnings and Precautions (
Drug Interactions Section
MAOIsMAOIs should not be used within 14 days of trazodone [see Warnings and Precautions (
Central Nervous System (CNS) DepressantsTrazodone may enhance the response to alcohol, barbiturates, and other CNS depressants.Cytochrome P450 3A4 InhibitorsIn vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with cytochrome P450 3A4 (CYP3A4) inhibitors. The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%. Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were coadministered. It is likely that ketoconazole, indinavir, and other CYP3A4 inhibitors such as itraconazole may lead to substantial increases in trazodone plasma concentrations with the potential for adverse effects. If trazodone is used with a potent CYP3A4 inhibitor, the risk of cardiac arrhythmia may be increased [see Warnings andPrecautions (
5.4)] and a lower dose of trazodone should be considered.
Cytochrome P450 Inducers (e.g., Carbamazepine)Carbamazepine induces CYP3A4. Following coadministration of carbamazepine 400 mg per day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone and m-chlorophenlypiperazine (an active metabolite) by 76% and 60% respectively, compared to pre-carbamazepine values. Patients should be closely monitored to see if there is a need for an increased dose of trazodone when taking both drugs.Digoxin and PhenytoinIncreased serum digoxin or phenytoin levels have been reported in patients receiving trazodone concurrently with either of these drugs. Monitor serum levels and adjust dosages as needed.Serotonergic DrugsBased on the mechanism of action of trazodone and the potential for serotonin syndrome, caution is advised when trazodone is coadministered with other drugs that may affect the neurotransmitter systems [see Warnings and Precautions (
NSAIDs, Aspirin, or Other Drugs Affecting Coagulation or BleedingDue to a possible association between serotonin modulating drugs and gastrointestinal bleeding, patients should be monitored for and cautioned about the potential risk of bleeding associated with the concomitant use of trazodone and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding [seeWarnings and Precautions (
WarfarinThere have been reports of altered (either increased or decreased) prothrombin times in taking both warfarin and trazodone.
Use In Specific Populations Section
8.1 PregnancyTeratogenic EffectsPregnancy Category CTrazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in two studies using the rat when given at dose levels approximately 30 to 50 times the proposed maximum human dose. There was also an increase in congenital anomalies in one of three rabbit studies at approximately 15 to 50 times the maximum human dose. There are no adequate and well-controlled studies in pregnant women. Trazodone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.8.3 Nursing MothersTrazodone and/or its metabolites have been found in the milk of lactating rats, suggesting that the drug may be secreted in human milk. Caution should be exercised when trazodone is administered to a nursing woman.8.4 Pediatric UseSafety and effectiveness in the pediatric population have not been established [see Boxed Warning and Warnings and Precautions (
5.1)]. Trazodone hydrochloride should not be used in children or adolescents.
8.5 Geriatric UseReported clinical literature and experience with trazodone has not identified differences in responses between elderly and younger patients. However, as experience in the elderly with trazodone hydrochloride is limited, it should be used with caution in geriatric patients.8.6 Renal ImpairmentTrazodone has not been studied in patients with renal impairment. Trazodone should be used with caution in this population.8.7 Hepatic ImpairmentTrazodone has not been studied in patients with hepatic impairment. Trazodone should be used with caution in this population.
Drug Abuse And Dependence Section
9.1 Controlled SubstanceTrazodone hydrochloride tablets are not a controlled substance.9.2 AbuseAlthough trazodone hydrochloride has not been systematically studied in preclinical or clinical studies for its potential for abuse, no indication of drug-seeking behavior was seen in the clinical studies with trazodone hydrochloride. However, it is difficult to predict the extent to which a CNS-active drug will be misused, diverted, and abused. Consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of trazodone hydrochloride (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).
Overdosage Section
10.1 Human ExperienceDeath from overdose has occurred in patients ingesting trazodone and other CNS depressant drugs concurrently (alcohol; alcohol and chloral hydrate and diazepam; amobarbital; chlordiazepoxide; or meprobamate).The most severe reactions reported to have occurred with overdose of trazodone alone have been priapism, respiratory arrest, seizures, and ECG changes, including QT prolongation. The reactions reported most frequently have been drowsiness and vomiting. Overdosage may cause an increase in incidence or severity of any of the reported adverse reactions.10.2 Management of OverdoseThere is no specific antidote for trazodone hydrochloride overdose.Treatment should consist of those general measures employed in the management of overdosage with any drug effective in the treatment of major depressive disorder.Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs.General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Forced diuresis may be useful in facilitating elimination of the drug.In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.
Description Section
Trazodone hydrochloride, USP is an antidepressant chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. Trazodone hydrochloride, USP is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4, 3-a]pyridin-3(2H)-one hydrochloride. It is a white, odorless crystalline powder which is freely soluble in water. The structural formula is represented as follows:Each tablet, for oral administration, contains 50 mg, 100 mg or 150 mg of trazodone hydrochloride, USP. In addition, each tablet contains colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose and sodium starch glycolate.
Clinical Pharmacology Section
12.1 Mechanism of ActionThe mechanism of trazodone's antidepressant action is not fully understood, but is thought to be related to its potentiation of serotonergic activity in the CNS.12.2 PharmacodynamicsPreclinical studies have shown that trazodone selectively inhibits neuronal reuptake of serotonin and acts as an antagonist at 5-HT-2A/2C serotonin receptors.Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system.Trazodone antagonizes alpha 1-adrenergic receptors, a property which may be associated with postural hypotension.12.3 PharmacokineticsAbsorptionIn humans, trazodone hydrochloride is well absorbed after oral administration without selective localization in any tissue. When trazodone hydrochloride is taken shortly after ingestion of food, there may be an increase in the amount of drug absorbed, a decrease in maximum concentration and a lengthening in the time to maximum concentration. Peak plasma levels occur approximately one hour after dosing when trazodone hydrochloride is taken on an empty stomach or 2 hours after dosing when taken with food.MetabolismIn vitro studies in human liver microsomes show that trazodone is metabolized, via oxidative cleavage, to an active metabolite, m-chlorophenylpiperazine (mCPP) by CYP3A4. Other metabolic pathways that may be involved in the metabolism of trazodone have not been well characterized. Trazodone is extensively metabolized; less than 1% of an oral dose is excreted unchanged in the urine.EliminationIn some patients trazodone may accumulate in the plasmaProtein BindingTrazodone is 89 to 95% protein bound in vitro at concentrations attained with therapeutic doses in humans.
Nonclinical Toxicology Section
13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityNo drug- or dose-related occurrence of carcinogenesis was evident in rats receiving trazodone in daily oral doses up to 300 mg/kg for 18 months.
Clinical Studies Section
The efficacy and safety of trazodone hydrochloride was established from both inpatient and outpatient trials of the trazodone immediate release formulation in the treatment of major depressive disorder.
How Supplied Section
Trazodone hydrochloride tablets USP are available as follows:50 mg: White, round, compressed tablet, debossed "PLIVA 433" on one side and scored on the other side. Available in bottles of 100, 500 and 1000.100 mg: White, round, compressed tablets, debossed "PLIVA 434" on one side and scored on the other side. Available in bottles of 100, 500 and 1000 Tablets and Unit Dose Blisters of 100 (10 x 10) Tablets.150 mg: White, trapezoid, flat-face, beveled edge tablet, scored and debossed as "PLIVA" and "441" on one side and tri-scored and debossed as "50" in each section on the other side. Available in bottles of 100 and 500 Tablets.Directions for using the correct score when breaking the tablet please refer to the following:- For 50 mg, break the score on either the left or right side of the tablet (one-third of a tablet).- For 75 mg, break the score down the middle of the tablet (one-half of a tablet).- For 100 mg, break the score on either the left or right side of the tablet (two-thirds of a tablet).- For 150 mg, use the entire tablet.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
Patient Medication Information Section
- See FDA-approved Medication Guide17.1 Information for PatientsPrescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with trazodone hydrochloride and should counsel them in its appropriate use.Patients should be warned that:There is a potential for increased risk of suicidal thoughts especially in children, teenagers and young adults.The following symptoms should be reported to the physician: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania and mania.They should inform their physician if they have a history of bipolar disorder, cardiac disease or myocardial infarction.Serotonin syndrome could occur and symptoms may include changes in mental status (e.g., agitation, hallucinations, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, and hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, and diarrhea).Trazodone hydrochloride has been associated with the occurrence of priapism.There is a potential for hypotension, including orthostatic hypotension and syncope.There is a potential risk of bleeding (including life-threatening hemorrhages) and bleeding related events (including ecchymosis, hematoma, epistaxis, and petechiae) with the concomitant use of trazodone hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding.Withdrawal symptoms including anxiety, agitation and sleep disturbances, have been reported with trazodone. Clinical experience suggests that the dose should be gradually reduced.Patients should be counseled that:Trazodone may cause somnolence or sedation and may impair the mental and/or physical ability required for the performance of potentially hazardous tasks. Patients should be cautioned about operating hazardous machinery, including automobiles until they are reasonably certain that the drug treatment does not affect them.Trazodone may enhance the response to alcohol, barbiturates, and other CNS depressants.Women who intend to become pregnant or who are breastfeeding should discuss with a physician whether they should continue to use trazodone, since use in pregnant and nursing women is not recommended.Important Administration Instructions:Trazodone hydrochloride tablets should be swallowed whole or broken in half along the score line.Trazodone hydrochloride tablets should be taken shortly after a meal or light snack.Manufactured In Croatia By:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured For:TEVA PHARMACEUTICALS USASellersville, PA 18960Rev. C 7/2012Medication guideTrazodone hydrochloride tablets USPRead the Medication Guide that comes with trazodone hydrochloride tablets before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk to your healthcare provider or pharmacist if there is something you do not understand or you want to learn about trazodone hydrochloride tablets.What is the most important information I should know about trazodone hydrochloride tablets?Antidepressant medicines, depression or other serious mental illnesses, and suicidal thoughts or actions: Talk to your healthcare provider about: • All risks and benefits of treatment with antidepressant medicines • All treatment choices for depression or other serious mental illnesses1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have or have a family history of bipolar illness (also called manic- depressive illness) or suicidal thoughts or actions.3. How can I watch for and try to prevent suicidal thoughts and actions?Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts or feelings.Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms.Call a healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:Thoughts about suicide or dyingAttempts to commit suicideNew or worse depressionNew or worse anxietyFeeling very agitated or restlessPanic attacksTrouble sleeping (insomnia)New or worse irritabilityActing aggressive, being angry or violentActing on dangerous impulsesAn extreme increase in activity and talking (mania)Other unusual changes in behavior or moodWhat else do I need to know about antidepressant medicines?Never stop an antidepressant medicine without first talking to a healthcare provider. Stopping an antidepressant medicine suddenly can cause other symptoms.Antidepressants are medicines used to treat depression and other illnesses. It is important to discuss all the risks of treating depression and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider, not just the use of antidepressants.Antidepressant medicines have other side effects. Talk to your healthcare provider about the side effects of your medicines.Antidepressant medicines can interact with other medicines. Know all of the medicines that you take. Keep a list of all medicines to show your healthcare provider. Do not start new medicines without first checking with your healthcare provider.4. Trazodone hydrochloride tablets are not approved for use in children. Talk to your healthcare provider for more information.What are trazodone hydrochloride tablets?Trazodone hydrochloride tablets are a prescription medicine used to treat major depressive disorder in adults.What should I tell my healthcare provider before taking trazodone hydrochloride tablets?Before you take trazodone hydrochloride tablets tell your healthcare provider if you: • have heart problems, including QT prolongation or a family history of it • have ever had a heart attack • have bipolar disorder • have liver or kidney problems • have other serious medical conditions • are pregnant or plan to become pregnant. Trazodone hydrochloride tablets may harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant. • are breastfeeding or plan to breastfeed. It is not known if trazodone hydrochloride tablets passes into your breast milk. You and your healthcare provider should decide if you will take trazodone hydrochloride tablets or breastfeed. • have taken a Monoamine Oxidase Inhibitor (MAOI) or if you have stopped taking an MAOI in the last 2 weeks.Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.Using trazodone hydrochloride tablets with certain other medicines can affect each other causing serious side effects.Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.How should I take trazodone hydrochloride tablets? • Take trazodone hydrochloride tablets exactly as your healthcare provider tells you. • Trazodone hydrochloride tablets should be taken shortly after a meal or light snack. • If you feel drowsy after taking trazodone hydrochloride tablets, talk to your healthcare provider. Your healthcare provider may change your dose or the time of day you take your trazodone hydrochloride tablets. • Do not stop taking trazodone hydrochloride tablets without talking to your healthcare provider. • Trazodone hydrochloride tablets should be swallowed whole or broken in half along the score line. Do not chew or crush trazodone hydrochloride tablets. Tell your healthcare provider if you cannot swallow trazodone either whole or as a half tablet. • If you take too much trazodone hydrochloride, call your doctor or go to the nearest emergency room right away.What should I avoid while taking trazodone hydrochloride tablets? • Do not drive, operate heavy machinery, or do other dangerous activities until you know how trazodone hydrochloride tablets affect you. Trazodone hydrochloride tablets can slow your thinking and motor skills. • Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking trazodone hydrochloride tablets until you talk with your healthcare provider. Trazodone hydrochloride tablets may make your sleepiness or dizziness worse if you take it with alcohol or other medicines that cause sleepiness or dizziness.What are the possible side effects of trazodone hydrochloride tablets?Trazodone hydrochloride tablets can cause serious side effects or death. See "What is the most important information I should know about trazodone hydrochloride tablets?"Serious side effects include: • Serotonin syndrome. Symptoms of serotonin syndrome include: agitation, hallucinations, problems with coordination, fast heartbeat, tight muscles, trouble walking, nausea, vomiting, diarrhea. • Feeling high or in a very good mood, then becoming irritable, or having too much energy, feeling like you have to keep talking or do not sleep (mania). • Irregular or fast heartbeat or faint (QT prolongation). • Low blood pressure. You feel dizzy or faint when you change positions (go from sitting to standing). • Unusual bruising or bleeding. • Erection lasting for more than 6 hours (priapism). • Low sodium in your blood (hyponatremia). Symptoms of hyponatremia include: headache, feeling weak, feeling confused, trouble concentrating, memory problems and feeling unsteady when you walk. • Withdrawal symptoms. Symptoms of withdrawal can include anxiety, agitation, and sleep problems. Do not stop taking trazodone hydrochloride tablets without talking to your healthcare provider.Get medical help right away, if you have any of the symptoms listed above.The most common side effects of trazodone hydrochloride tablets include: • Sleepiness • Dizziness • Constipation • Blurry visionTell your healthcare provider if you have any side effect that bothers you or that does not go away.These are not all the possible side effects of trazodone hydrochloride tablets. For more information, ask your healthcare provider or pharmacist.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should I store trazodone hydrochloride tablets? • Store trazodone hydrochloride tablets between 20° to 25°C (68° to 77°F). • Keep in tight container • Keep out of the light • Safely throw away medicine that is out of date or no longer needed.Keep trazodone hydrochloride tablets and all medicines out of the reach of children.General information about the safe and effective use of trazodone hydrochloride tablets.Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use trazodone hydrochloride tablets for a condition for which it was not prescribed. Do not give trazodone hydrochloride tablets to other people, even if they have the same symptoms that you have. It may harm them.This Medication Guide summarizes the most important information about trazodone hydrochloride tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about trazodone hydrochloride tablets that is written for health professionals.For more information, call 1-866-832-8537, MEDICAL AFFAIRS.What are the ingredients in trazodone hydrochloride tablets?Active ingredient: trazodone hydrochloride, USPInactive ingredients: colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose and sodium starch glycolate.This Medication Guide has been approved by the U.S. Food and Drug Administration.Manufactured In Croatia By:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaTEVA PHARMACEUTICALS USASellersville, PA 18960Iss. 7/2012
* Please review the disclaimer below.


text:
15 October 2008
The Sazerac Cocktail
I balanced tradition and personal preference with my application of this recipe. I used two shots of Sazerac Rye and three dashes of Peychaud's Bitters (both now made in Kentucky), along with a few drops of French Pastis Henri Bardouin and a bit of sugar to sweeten it all. I felt the pastis substitution would provide the necessary anise/herbal kick. (I've had real German and Czech absinthe; I still prefer pastis.) Everything was stirred together in a chilled tumbler, and a slice of lemon peel was tossed in for garnish (not pictured).
Rye is a little more peppery and spicy than normal whiskey, and Peychaud's Bitters are closer to cherry cough syrup than Angostura Bitters. While all of this sounds a little strange, the cocktail really did come together well. I felt it worked better with a couple of ice cubes in it, and that allowed you to savor it properly over a half hour.
3 comments:
- Samantha Dugan said...
I have had real Absinthe and I too prefer Pastis without a doubt...seems less sweet and has more depth of flavor. I had a question for you, I drink Pastis a lot and have tried the Henri Bardouin that you used in your cocktail, I found that it had a pretty pronounced cinnamon flavor, do you get that? I am wondering if they make more than one and I got a spiced one? Just curious if you noticed that.
- 15 October, 2008 07:41
- Benito said...
I've never noticed a cinnamon flavor, however this is the only pastis I've tried and I'm not an expert on the subject (the options are limited in this part of the country, and I'd tried HB in a bar previously). The website seems to only list one pastis, but the company makes a wide range of spirits.
Any other producers you'd recommend?
- 15 October, 2008 08:08
- Samantha Dugan said...
My go-to Pastis right now is Granier Mon Pastis, seems to have just a tad less sweetness which suits my palate and to top it off it is half the price of Pernod...rare that I prefer the lesser expensive but man do I love it when it happens.
- 15 October, 2008 08:33


text:
Ideal Triple Excellent Make (EX EX EX)
Manufacturers of ideal cut triple excellent GIA Russian make rounds from 1 carat, 1.5 carat up to 2 carats.
Excellent Make Russian Melee
Wholesalers of full cut excellent make of small round Russian melee from 0.04ct to 0.29 carat.
Fancy Color
Suppliers of fancy color pink diamonds directly from the Australian Argyle diamond mine, mainly faint pink, fancy intense pink and fancy vivid pink including the famous purplish pink color. Our special aftermarket imaging and video equipment allows us to show you the actual color of the stone in High Definition and in Three Dimensions.


text:
Chevrolet has a lot of important nameplates to promote this year, which is why they've returned to Super Bowl advertising after skipping last year's game. And what better way to sell the 2014 Corvette and Silverado?
The company posted two new 60-second ads to their YouTube channel over the weekend, one for the Corvette and Silverado, respectively.
"Machine" reminds you the 2014 Corvette is a serious performance car now, if we haven't done enough of that already.
The one for the 2014 Silverado is a bit of a tearjerker and somewhat reminiscent a plot line from Nashville. In all serious, though, it's a nice ad that's going to hit that target truck buyer well.
But are they big enough for the Super Bowl? We'll have to find out.


text:
This article was reported by Mail & Guardian.
The Mail & Guardian reported that HIV prevalence among South Africans rose to 12.2 percent in 2012 (6.4 million HIV-infected people), according to the Human Sciences Research Council's (HRSC) National HIV Prevalence, Incidence, and Behavior Survey. The national HIV household survey would provide benchmarks to evaluate the health department's 2012-2016 national strategic plans for HIV, TB, and STDs. The 2012 survey included approximately 38,000 people, 29,000 of whom agreed to have HIV testing. Based on the latest survey, South Africa was unlikely to reach the target of reducing HIV transmission by 50 percent by 2016. South Africa had the highest HIV incidence in the world.
HSRC attributed increased HIV prevalence to new HIV infections and to successful antiretroviral therapy (ART) that resulted in longer, healthier lives for HIV-infected people. Access to ART "almost doubled" from 2008 to 2012; approximately one-third of South Africa's HIV-infected people accessed ART in 2012.
HIV incidence among females ages 15-24 was four times higher than males; incidence among female teenagers was eight times higher than among male teens. Black African females ages 20-34 had the highest incidence of all groups. HIV incidence was considerably lower among married South Africans than among cohabiting unmarried people.
The highest HIV incidence occurred among black Africans (15 percent), "colored people" (3.1 percent), Indians or Asians (0.8 percent), and whites (0.3 percent). Black Africans were more likely to live in rural areas with less access to preventive health services and were less likely to be married. Female teenagers were more likely to have sex with partners more than five years older than they were. The lowest condom use rate occurred among unmarried, cohabiting people ages 15-49. HSRC Chief Executive Olive Shisana urged that prevention strategies should align with "underlying sociocultural norms in the affected communities."


text:
- Description
- Product Reviews
- Product Video
- Marine Vinyl Color Chart
SEM M25243, Sterling Burgandy, Marine Vinyl Paint
Matched to Sterling Burgandy vinyl color.
SEM Marine Vinyl Coat is a modified version of SEM Color Coat which features increased UV inhibitors to withstand the harsh environment boat seats are subjected to. The color pallet has been matched to 25 of the most popular boat and personal watercraft colors.
Marine Vinyl Paint Application:
- Wash the surface with hot water and a degreasing soap. For mildew or molded surfaces use a weak solution of bleach and water to remove then rinse well!
- Clean surface with SEM 39362 SEM Soap and a gray scuff pad then clean with SEM 38343 Vinyl Prep.
- Spray 2-3 coats of Marine Vinyl Paint allowing 10-15 minutes between each coat.
- The substrate should not be subjected to heavy abuse or abrasion for 24 hours.
Salesman Note: Before applying SEM Marine Vinyl, make certain you follow all the steps above. If the surface is not throughly clean the product will not adhere to it's full potential and will be subject to quick wearing and peeling. Please don't skip steps thinking you'll save money, You won't. In fact, it will cost you money to re-do it.
Related Products
SEM 39362, SEM Soap
SEM 39643, Tac Free Protective Topcoat


text:
Grizzlies Top T-wolves 109-92
MEMPHIS, Tenn. (AP) — Mike Conley had 23 points and six assists, Marc Gasol added 14 and 12 rebounds and the Memphis Grizzlies built an early lead and easily dispatched the short-handed Minnesota Timberwolves 109-92 on Monday night.
Zach Randolph finished with 17 points for Memphis, while Tayshaun Prince and Ed Davis added 12 points apiece. Mike Miller scored 11 as Memphis won its 10th straight home game.
Kevin Love led the Timberwolves with 16 points, but shot 6-of-18 from the field, part of Minnesota shooting 38 percent for the game. Corey Brewer had 15 points and Kevin Martin finished with 13. Gorgui Dieng, in the starting lineup because of injuries on Minnesota's front line, finished with 11 points and 17 rebounds.
The victory left Memphis in the seventh spot in the Western Conference playoff race, a half-game ahead of Dallas and Phoenix.


text:
Collins: Perfect evening at the Backstage
My family and I have just returned from the Backstage Theatre's production of "A Christmas Carol." What a wonderful evening! From the warm welcome received on arrival, through the lovely intimate nature of the theatre, to the magnificent production we witnessed, everything was perfect.
It is a tribute to the people of Breckenridge that a production of such quality and innovation can be created in a local theatre like this. The skiing has been good, but this evening has probably been the highlight of our holiday. I would exhort all the residents of the town to catch this performance whilst they can. Yours sincerely,
David Collins, Mansfield, U.K.
Start a dialogue, stay on topic and be civil.
If you don't follow the rules, your comment may be deleted.


text:
- Income Investing
Bonds Face Threat From Strong Spring Data – Morgan Stanley
- Order Reprints
- Print Article
Count Morgan Stanley Wealth Management among those who think the spate of weak economic data this winter will give way to much stronger economic readings as the weather warms up. Morgan Stanley fixed-income strategists Kevin Flanagan, John Dillon and Jonathan Mackay say Treasuries benefited during the first quarter from being "stuck between a safe-haven bid emanating from the Ukraine/Russia situation and recent domestic developments... and a Federal Reserve seemingly intent on winding down Quantitative Easing (QE) this year," but could be in for a rough ride over the next few quarters:
The strong performance in investment grade credit—and specifically in long-duration assets, based on the rally in the Treasury market—seemed unsustainable and was likely to reverse quickly as soon as stronger data started showing up. Barring a shock from Russia or China, we would expect the next month or two of data to generally surprise to the upside, which should continue to put upward pressure on bond yields and is likely to reverse the strong performance year to date in longer-duration assets.
Morgan Stanley homes in on some yield-curve movements that are worth keeping an eye on:
The "belly" of the curve, the five-year/10-year spread, has tightened to less than 100 basis points, the narrowest reading since early May of last year. To us, this reflects the market uncertainty surrounding the timing of the Fed's first policy-rate hike, yet we do not see Janet Yellen, the new Fed chairman, making any significant changes from the policies her predecessor put in place....
As long as rates move higher, the yield curve should start flattening, meaning short rates would move more significantly than long rates.
As for where to invest, Morgan Stanley offers tepid endorsements of both junk bonds and munis:
In high yield, valuations are somewhat rich and the price upside appears limited. Still, in today's low-yield world, an average coupon of more than 7%, coupled with strong credit quality and low default rates, makes high yield a compelling trade….
[W]e expect better entry points [into the muni market] in the coming weeks due to stronger economic data and moderately increased muni supply, along with a possible bout of volatility from geopolitical developments…. On a longer-term basis, we continue to remain constructive on tax-exempt municipal bonds and believe that credit selection will be a primary determinant of performance this year.


text:
The annual TriClub Global Rankings provide registered IRONMAN TriClubs a way to measure their race performance against other TriClubs enrolled in the program.
TriClub points are calculated using IRONMAN's age group ranking system. Any time an athlete races for their club at either an IRONMAN or IRONMAN 70.3 they generate age group ranking points for themselves as well as their TriClub. But unlike the age group ranking system where an athlete's top three race performances are scored, TriClub points are cumulative over the course of a calendar year. The more a TriClub member races with IRONMAN, the greater number of points are credited to the clubs ranking.
Clubs are divided into club divisions based on the size of the club. For more information regarding the division sizes, division criteria, or accumulated points please email [email protected].
Clubs can verify the points they have earnt by checking the rankings.
TriClub Ranking Points System
Using the Age Group Ranking Points system (AGR); the total available points for a full-distance IRONMAN is 5,000 points and for an IRONMAN 70.3 is 3,500 points.
AGR points are calculated based on the athlete's race finish time behind the first finisher in his/her age group. Points continue to drop as the race time increases, until the points reach a "point floor," at which point they don't drop any further and every athlete after this will receive the value of the "point floor." For a full-distance IRONMAN the "point floor" is 1,000 points and for an IRONMAN 70.3 the "point floor" is 700.
There is a value to the minutes and seconds in each race distance. For a full-distance IRONMAN points diminish at a rate of approximately 12 points per minute and for an IRONMAN 70.3 points diminish at a rate of approximately 18 points per minute.
Example: If you win your age group at an IRONMAN event, you are awarded 5,000 points. If you finish in second place a minute behind the leader, you are awarded 4,988 points.
|AGR Points System Break Down
|Event Distance
|Maximum Points
|Minimum Points
|Rate of Decline*
|Time to Floor**
|12 points/
|5.5 hours
|18 points/
|2.5 hours
|5i50/ Olympic
|21 points/
|30 minutes
|Sprint Distance Triathlon
|33 points/
|15 minutes
* Please note AGR and TriClub Ranking points will also count towards the Global TriClub Rankings and onsite TriClub Podium competition.
IRONMAN World Championship Events Extra Points.
For every TriClub member attending the IRONMAN World Championship and IRONMAN 70.3 World Championship your Club will earn an additional 700 AGR points. These points are assigned only to the TriClub and not to the individual athlete.
Example: If your Club has 3 members racing at IRONMAN World Championship and 1 member at IRONMAN 70.3 World Championship, the total additional points assigned to your Club will be 2800 points.